

Sexual Dysfunction Varies With Vulvodynia Type

BY HEIDI SPLETE

PENTAGON CITY, VA. — Women with complex vulvar pain reported greater decreases in sexual function but similar levels of sexual desire and frequency of intercourse, compared with women with provoked vestibulodynia, a study of 189 women shows.

Provoked vestibulodynia (PVD) is the most common subtype of vulvodynia, and it involves pain that is localized at the vaginal opening and triggered by sexual intercourse, said Kelly B. Smith, of Queens University in Kingston (Ont.).

But the characteristics and side effects of other forms of vulvodynia have not been well studied, Ms. Smith said.

To compare pain locations and sexual function between women with localized

But the complex pain and provoked vulvodynia groups had similar scores on measures of desire, sexual satisfaction, relationship quality, and sex frequency.

vs. generalized pain, Ms. Smith and her colleagues reviewed data from 72 women with provoked vestibulodynia, 44 women who reported complex vulvar pain (defined as pain not localized or provoked), and 73 controls. The results were presented at the annual meeting of the Society for Sex Therapy and Research.

All the women were in heterosexual relationships. The average age of the women who reported pain was 36 years, and the average age of the controls was 27 years. The women with PVD had experienced pain for an average of 7 years, and the women with complex pain had experienced pain for an average of 8 years. The participants were assessed using an online survey and the Female Sexual Function Index, the Golombok-Rust Inventory of Sexual Satisfaction, the Dyadic Adjustment Scale, and the Dyadic Sexual Communication Scale.

Most of the women with complex pain reported generalized and localized pain, both provoked and unprovoked. A woman could report pain over her whole vulvar region generally, and then report localized pain during intercourse, Ms. Smith explained. A total of 41% of the women with complex pain reported generalized and localized pain, in addition to provoked and unprovoked pain.

Overall, the women with complex pain had worse sexual function, and more problems specifically with arousal, lubrication, orgasm, and penetration pain, compared to the women with PVD. But the complex pain and PVD groups had similar scores on measures of desire, sexual satisfaction, relationship quality, and sex frequency. "Even though women with pain were more sexually dysfunctional, they valued sex just as much as control women," she said.

The reported frequency of intercourse

was similar among women in the PVD group vs. the complex pain group, but a highly significant difference was found between the pain groups and the controls. The control women reported sex an average of 52 times during the last 6 months, compared with an average of 12 times in 6 months in the two pain groups.

There were no differences in terms of self-reported desire and no differences in sexual satisfaction between the complex

pain and PVD groups, and no significant differences were observed in overall relationship quality. "But when we looked at controls, the women with pain of any type had worse relationship quality compared to controls, and less affection and cohesion with their partners," Ms. Smith said.

The results support findings from previous studies, and the data suggest that vulvodynia has distinct pain characteristics and might be more complicated than

previously thought, Ms. Smith said.

The study was limited by a lack of information about sexual partners of women with PVD vs. those with complex pain, she noted.

Additional research is needed to address issues including the presentation and etiology of vulvodynia, as well as implications for treatment.

Ms. Smith had no financial conflicts to disclose. ■

Confidence
FOR PATIENTS AND PHYSICIANS

Designed to help gain & maintain a seal at the cervix.

HTA ProCerva™ Procedure Sheath
for the HTA® System

The HTA ProCerva Procedure Sheath is designed to combine the effectiveness of the HTA System therapy with the added confidence of the new cervical seal assist, creating a treatment with reproducible results for both physicians and their patients.

Boston Scientific
Delivering what's next.™

Refer to HTA System User's Manual provided with product for complete instructions for use.

INDICATIONS: The HTA System is a hysteroscopic thermal ablation device intended to ablate the endometrial lining of the uterus in premenopausal women with menorrhagia (excessive uterine bleeding) due to benign causes for whom childbearing is complete. **CONTRAINDICATIONS:** The HTA System is contraindicated for use in a patient: who is pregnant or wants to be pregnant in the future, as pregnancy after ablation can be dangerous to both mother and fetus; who has known or suspected endometrial carcinoma or premalignant change of the endometrium, such as adenomatous hyperplasia; who has active pelvic inflammatory disease or pyosalpinx; hydrosalpinx; who has any anatomical or pathologic condition in which weakness of the myometrium could exist, such as, prior classic cesarean section or transmural myomectomy; who has an intrauterine device in place; or who has active genital or urinary tract infection, e.g., cervicitis, endometritis, vaginitis, cystitis, etc., at the time of treatment. **POTENTIAL ADVERSE EFFECTS** that may occur include: thermal injury to adjacent tissue including cervix, vagina, vulva, and/or perineum; heated saline escaping from the device system into the vascular spaces; hemorrhage; perforation of uterus; complications with pregnancy (Note: pregnancy following ablation is dangerous to both the mother and the fetus); risks associated with hysteroscopy, post ablation tubal sterilization syndrome: infection or sepsis; complications leading to serious injury or death. **WARNINGS:** NOTE: Failure to follow any instructions or to heed any Warnings or Precautions could result in serious patient injury. **CAUTION: Federal Law (USA) restricts this device to sale by or on the order of a physician. The physician using the device must be trained in diagnostic hysteroscopy.**

© 2009 Boston Scientific Corporation or its affiliates. All rights reserved. MVA410 5/09